NextPoint Therapeutics, Inc.
Leena Gandhi currently serves as Chief Medical Officer at NextPoint Therapeutics, Inc., leading innovative immuno-oncology therapeutics into clinical trials. Previously, Leena held the position of Director at the Center for Cancer Therapeutic Innovation and Associate Professor of Medicine at Dana-Farber Cancer Institute, managing a team of over 50 faculty and staff to advance early-phase clinical trials. Leena's experience includes serving as VP of Immuno-Oncology Development at Lilly Research Laboratories, where oversight of 13 agents in the clinical development process took place. Additionally, Leena directed the thoracic medical oncology program at New York University Perlmutter Cancer Center and contributed significantly as a Thoracic Oncologist at Dana-Farber Cancer Institute. Leena completed a Hematology/Oncology Fellowship at Massachusetts General Hospital and earned an M.D. from New York Medicine Jobs and a Ph.D. in Biochemistry and Molecular Biology from the University of California, Berkeley.
This person is not in any teams
NextPoint Therapeutics, Inc.
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.